Sean D. Sullivan
The fertility of our minds to invent health care technology must now be matched by a commitment to assess and identify its appropriate use.
EducationPhD University of California (Berkeley), 1992 (Health Economics)
MS University of Texas (Austin), 1986 (Pharmacy)
BS Oregon State University, 1983 (Pharmacy)
Contact Infoemail: firstname.lastname@example.org
office: H-375, Health Sciences Building
1959 NE Pacific Street
Seattle, WA 98195-7630
campus box: 357630
Sean D. Sullivan, BScPharm, MSc, PhD, is Professor and Associate Dean for Research at the University of Washington School of Pharmacy. He holds a joint appointment as Professor of Health Services in the School of Public Health, is Director of the UW Pharmaceutical Outcomes Research and Policy Program (PORPP) and co-Director of the University of Washington Centers for Comparative and Health Systems Effectiveness (CHASE Alliance). He holds adjunct appointments in the School of Medicine, the Public Health Sciences Division at the Fred Hutchinson Cancer Research Center, and at Group Health Research Institute.
He completed his bachelor's degree in pharmacy from Oregon State University in 1983, master's degree in administrative and economic sciences from the University of Texas in 1986 and PhD in health economics and policy from the University of California-Berkeley in 1991.
Dr. Sullivan has authored more than 300 journal articles, book chapters, task force reports and organizational and governmental publications. In many of these writings, he has assessed the evidence and applications of medical technology in relation to coverage and reimbursement decisions. His research interests include technology assessment, medical decision-making and economic evaluation of medical technology. He is the past chair of the Academy of Managed Care Pharmacy executive committee on the AMCP Format for Formulary Submissions - the United States evidence-based guidelines for formulary decision-making.
Dr. Sullivan is a member of the Medicare Evidence Development and Coverage Advisory Committee. He is also on the editorial boards of Value in Health, PharmacoEconomics, European Journal of Health Economics and Core Evidence. He is a past president of the International Society for Pharmacoeconomics and Outcomes Research.
Seal B, Sullivan SD, Ramsey S, Asche CV, Shermock KM, Sarma S, Zagadailov E, Farrelly E, Eaddy M. Evaluating treatments and corresponding costs of prostate cancer patients treated within an inpatient or hospital-based outpatient setting. Future Oncol. 2015 Feb;11(3):439-47. doi: 10.2217/fon.14.242. PMID: 25675125
Lee CI, Gold LS, Nelson HD, Chou R, Ramsey SD, Sullivan SD. Comparative effectiveness of imaging modalities to determine metastatic breast cancer treatment response. Breast. 2015 Feb;24(1):3-11. doi: 10.1016/j.breast.2014.11.009. Epub 2014 Dec 3. Review. PMID: 25479913
Hansen RN, Hackshaw MD, Nagar SP, Arondekar B, Deen KC, Sullivan SD, Ramsey SD. Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm. 2015 Jan;21(1):37-44. PMID: 25562771
Pauly MV, Sloan FA, Sullivan SD. Cost-effectiveness: the authors reply. Health Aff (Millwood). 2015 Jan 1;34(1):188. doi: 10.1377/hlthaff.2014.1374. PMID: 25561660
PI: Sullivan Dates: 10/1/2010 - 9/30/2013